FIGURE 2.

Treatment difference in adjusted mean change from baseline in mean 24-h SBP (a), 24-h DBP (b), and heart rate (c) at week 24 by antihypertensive background therapy. ^∗Treatment difference: difference in the adjusted means for linagliptin versus placebo at week 24; ^†analysis of covariance model includes baseline mean 24-h SBP, baseline log₁₀ (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect; ^‡analysis of covariance model includes baseline mean 24-h SBP, baseline log₁₀ (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline by treatment interaction as fixed effects; ^§analysis of covariance model includes baseline mean 24-h DBP, baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect; ^∗∗analysis of covariance model includes baseline mean 24-h DBP, baseline log₁₀ (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline by treatment interaction as fixed effects; ^††analysis of covariance model includes baseline mean 24-h heart rate, baseline log₁₀ (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect; ^‡‡analysis of covariance model includes baseline mean 24-h heart rate, baseline log₁₀ (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline by treatment interaction as fixed effects. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI, confidence interval.